A World of Opportunity: What to Expect from CPhI & P-MEC China

China’s healthcare market is currently experiencing double-digit growth, with indications that the market is primed for further expansion. Recent reforms at the Center for Drug Evaluation and the China Food and Drug Administration have accelerated review timelines for IND and NDA applications and removed a requirement to conduct new clinical trials in China for drugs approved in other countries. The combination of a friendlier regulatory environment and the extension of public health insurance policies to the vast majority of the Chinese population has greatly enhanced the appeal of the Chinese market to foreign pharma companies, driving new investment. 

CPhI & P-MEC China

Since its founding in 2001, CPhI & P-MEC China has become the premier pharmaceutical exhibition and networking event in Asia. Emerging as a sister show of CPhI Worldwide, the global exhibition has continued to grow independently over the last two decades and is now recognized by the industry as the most significant pharmaceutical trade event in Asia. Both CPhI China, which is devoted to pharmaceutical ingredients, and P-MEC, which focuses on pharmaceutical equipment, serve as industry pillars on their own and capture a tremendous audience together. Over 50,000 visitors from across the supply chain are expected to gather at the dual, co-located event, held annually at the Shanghai New International Expo Centre (SNIEC), for the purpose of networking, deal-making and idea exchange.

Simultaneous Co-located Trade Shows and China Pharma Week

With backing from prestigious global organizations — UBM EMEA, CCCMHPIE and UBM Sinoexpo — who have worked together to coordinate and co-organize the trade events, CPhI & P-MEC China 2019 uniquely represents every sector of the pharmaceutical industry. Attendees can look forward to broad, yet detailed coverage spanning the entire supply chain, with a range of industry segments, from APIs and excipients to finished dosage form, natural extracts, pharmaceutical equipment and machinery, lab equipment, veterinary drugs and feed, clean room and environmental protection, as well as biopharmaceuticals, pharmaceutical packaging and logistics and distribution, exhibiting. 

With the majority of the industry touching down in Shanghai for CPhI & P-MEC China, a concurrent “China Pharma Week” has emerged. During China Pharma Week, guests can expect conferences and activities tailored to visitors from around the world that provide relevant insights into the current and future state of the industry, both in China and abroad. 

The CPhI & P-MEC China Visitor Profile

The average visitor to CPhI & P-MEC China is a high-level decision maker with a top-tier title, such as C-suite member, manager or director at their organization. Owing to the international scope of the show, attendees can expect to meet with like-minded professionals that are globally represented, including Asia, Europe, America and Africa, among other regions. 

Of the visitors to CPhI & P-MEC China, 19.6% identify as president, chairman, CEO or general manager, while 30.09% are described as manager, project manager or department head. Approximately 25.78% of attendees work in the purchasing departments of their companies, 16.67% are employed in research and development, and 21.06% work in sales and marketing. Out of all surveyed CPhI & P-MEC China attendees, close to 50% have the ability to make decisions on behalf of their businesses.

Q1_CPhl_P-MEC China_sidebar

A World of Opportunity

Those that make the trip to Shanghai for CPhI & P-MEC China will expand their global horizons and make interesting new connections — including potential business partners from across the globe. This worldwide show hosted in China is a standout event in the industry and will no doubt be an unforgettable week for all. CPhI & P-MEC China will take place on June 18–20, 2019 at SNIEC Shanghai. 

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

CPhI & P-MEC China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your One-stop Shop pharma platform in Asia.